


# BPS19

63<sup>RD</sup> ANNUAL MEETING OF THE BIOPHYSICAL SOCIETY

BALTIMORE, MARYLAND • MARCH 2–6, 2019



**Tuesday, March 5**

**9:30 am – 11:00 am**

**Room 303**

**Sophion Bioscience A/S**

## **ELECTROPHYSIOLOGICAL CHARACTERIZATION USING AUTOMATED PATCH CLAMP (QPATCH AND QUBE) OF hiPSC-DERIVED NEUROLOGICAL DISEASE MODELS, NEW AUTOMATED PATCH CLAMP ION CHANNEL ASSAYS FOR CiPA CARDIAC SAFETY TESTING (DYNAMIC hERG and LQT3 LATE NAV1.5) AND NAV1.7 DRUG DISCOVERY**

Successful ion channel drug discovery requires the integration of multiple technologies and workflows. Sophion Bioscience is a leader in automated patch clamp technology, providing medium to high throughput, automated patch clamp to the pharmaceutical industry and universities. The QPatch and Qube are fully automated patch clamp systems, executing simultaneous 8, 16, 48 or 384 parallel patch clamp recordings in conjunction with computer controlled liquid handling and on-board cell handling. Sophion partners with other biotech companies to create robust, ion channel and electrophysiological workflows for drug development for ion channel targets. During this workshop, three industry speakers will provide insight into the drug discovery process. Dr Kadla Roskva Rosholm will present how hiPSC-derived neurological disease models have been characterized by use of high throughput electrophysiology at Sophion Bioscience. Next, Dr Marc Rogers from Metrion Biosciences will present their development of new automated patch clamp ion channel assays for CiPA cardiac safety testing: dynamic hERG and LQT3 late Nav1.5. Finally, Dr Brian Moyer will present on Amgen's Nav1.7 drug discovery program.

### **Speakers**

*Kadla Roskva Rosholm, Application Scientist, Sophion Bioscience A/S*

*Marc Rogers, Chief Scientific Officer, Metrion Biosciences*

*Brian Moyer, Scientific Director, Department of Neuroscience, Amgen*